InvestorsHub Logo
Followers 120
Posts 3168
Boards Moderated 0
Alias Born 02/21/2010

Re: None

Saturday, 08/09/2014 11:32:56 AM

Saturday, August 09, 2014 11:32:56 AM

Post# of 25
Stock Split Filing on NVSOS and 8K's

Upon effect of the forward split, our authorized capital will increase from 75,000,000 shares of common stock to 525,000,000 shares of common stock and correspondingly, our issued and outstanding shares of common stock will increase from 4,250,000 to 29,750,000 shares of common stock, all with a par value of $0.001.
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10139249

Previous Stock Value:
Par Value Shares: 75,000,000 Value: $ 0.001
No Par Value Shares: 0
Total Authorized Capital: $ 75,000.00

New Stock Value:
Par Value Shares: 525,000,000 Value: $ 0.001
No Par Value Shares: 0
Total Authorized Capital: $ 525,000.00
http://nvsos.gov/sosentitysearch/corpActions.aspx?lx8nvq=awQd4ZhBS5iI4ychwZi6qg%253d%253d&CorpName=ARGAN+BEAUTY+CORP.

Company Website might come up here: http://arganbeautycorp.com
Domain Name: ARGANBEAUTYCORP.COM
Registrar URL: http://www.godaddy.com
Registrant Name: Vitaliy Gorelik
Registrant Organization:
Name Server: NS53.DOMAINCONTROL.COM
Name Server: NS54.DOMAINCONTROL.COM
DNSSEC: unsigned

New CEO added too:
Burt Ensley, Ph.D. – Chief Executive Officer

Burt Ensley, Ph.D., is the founder of Protein Genomics, Inc. and DermaPlus, Inc., Arizona-based biotechnology companies involved in wound healing, tissue regeneration and skin care.

His professional career began in 1981 when he was hired by Amgen, Inc., a start-up biotech firm in Thousand Oaks, California, that he helped become the largest such company in the world within 10 years. Amgen now has 40,000 employees and $12 billion in annual revenue.

2

In 1989, Dr. Ensley left Amgen to serve as director of advanced technologies for Envirogen, Inc. There, he led research and field demonstrations of biological and physical/chemical technologies for the treatment of hazardous wastes from the company’s inception until its public offering in 1992. He then became a founder and the president, chief executive officer and director of Phytotech, Inc., a biotechnology company using plants for the treatment of contaminated soil and water. He raised financing for Phytotech of $5 million in equity and $2 million in debt from inception to sale of the business in June 1999.

In 1999, Dr. Ensley founded Nucycle Therapy, Inc., a biotechnology company involved in discovering, developing and commercializing unique nutritional supplements and high value nutraceutical and therapeutic products from plants. He served as the company’s chief executive officer from 1999 to 2001. The company was able to scale-up the manufacture of 50 million doses of plant-based nutritional mineral supplements, and was sold to Integrated Biopharma, a publicly traded entity, in 2001.

In 2004, Dr. Ensley founded Protein Genomics, Inc., a privately held genomics-based biopolymer company. The company designs and manufactures protein monomers and polymers of human structural molecules with applications in wound healing, tissue repair and personal care products. These products are designed directly from the mRNA sequences of individuals and population groups. Dr. Ensley currently acts as chairman and chief executive officer of Protein Genomics, Inc.

Dr. Ensley was elected to Fellowship in the American Academy of Microbiology in recognition of his research accomplishments. His professional affiliations have included membership in the board of directors and co-chair of The BIO5 Institute at the University of Arizona; board of trustees at the Biotechnology Council of New Jersey; board of directors of the Natural History Museum at the University of Kansas; the American Association for the Advancement of Science; the American Society for Microbiology; service on the National Research Council Committee on Catalysis; and on the biology directorate advisory committee of the National Science Foundation. He is an adjunct professor at Northern Arizona University.

He holds his Ph.D. degree in microbiology from the University of Georgia (1979), his master’s degree in biology from the University of New Mexico (1976), and bachelor’s degree in biology from the University of New Mexico (1974).

Dr. Ensley has 30 publications in peer-reviewed scientific literature and holds 19 issued and 2 pending US patents.

Dr. Ensley served in the US Army from August 1968 until May, 1971, graduating from the MACV Recondo School and serving with the 5th Special Forces Group, 1st Special Forces (Airborne) in Nha Trang, Vietnam. He was decorated twice (BSM and ARCOM) for service in combat.

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10138271